News & Trends

• 302026-04

  Clinical trial application for Salubris’cyclic peptide drug SAL0167 accepted for the treatment of hyperlipidemia

• 212026-04

  The latest clinical trial data for Salubris' novel anticancer drug, JK06, presented at the AACR, demonstrated favorable safety and efficacy profiles in patients with non-small cell lung cancer and breast cancer

• 022026-04

  Salubris siRNA New Drug SAL0132 Releases Phase I Clinical Data: Single Dose Lowers AGT by Over 90%, Demonstrating Potential for Ultra-Long-Acting Antihypertensive Effect

• 272026-03

  Salubris Obtains Exclusive License for Pruritus Drug STC007 Collaboration Announcement

• 252026-03

  Salubris’ Investigational Drug SAL0145 Approved for Clinical Trial for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)

• 242026-03

  Salubris’ Self-Developed Investigational Drug SAL0150 Approved for Clinical Trial for the Treatment of Type 2 Diabetes and Obesity